SiBone (NASDAQ:SIBN) CEO Laura Francis Sells 3,923 Shares

SiBone (NASDAQ:SIBN) CEO Laura Francis sold 3,923 shares of SiBone stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $20.02, for a total value of $78,538.46. Following the completion of the transaction, the chief executive officer owned 317,463 shares of the company’s stock, valued at approximately $6,355,609.26. This represents a 1.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Laura Francis also recently made the following trade(s):

• On Thursday, August 20th, Laura Francis sold 51,884 shares of SiBone stock. The stock was sold at an average price of $19.46, for a total value of $1,009,662.64.

SiBone Stock Performance

Shares of SIBN stock opened at $19.96 on Friday. The company has a current ratio of 9.15, a quick ratio of 7.55 and a debt-to-equity ratio of 0.20. SiBone has a 12-month low of $11.48 and a 12-month high of $21.89. The business’s 50 day moving average is $17.49 and its two-hundred day moving average is $15.33. The company has a market capitalization of $885.23 million, a P/E ratio of -58.71 and a beta of 0.66.

SiBone (NASDAQ:SIBN) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.06. The business had revenue of $56.01 million during the quarter, compared to analysts’ expectations of $55.34 million. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%. Analysts expect that SiBone will post -0.4 EPS for the current fiscal year.

Analyst Ratings Changes

SIBN has been the topic of several research analyst reports. Weiss Ratings upgraded shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday. Truist Financial restated a “buy” rating and set a $23.00 price target (up from $21.00) on shares of SiBone in a research report on Tuesday, August 4th. TD Cowen raised their price target on shares of SiBone from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Finally, UBS Group lifted their price objective on SiBone from $24.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $24.17.

Institutional Investors Weigh In On SiBone

A number of large investors have recently modified their holdings of SIBN. First Light Asset Management LLC raised its position in shares of SiBone by 162.4% in the fourth quarter. First Light Asset Management LLC now owns 5,032,904 shares of the company’s stock valued at $99,249,000 after buying an additional 3,115,001 shares during the last quarter. Granahan Investment Management LLC boosted its position in SiBone by 97.6% during the first quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company’s stock worth $21,965,000 after acquiring an additional 858,942 shares during the last quarter. Paradigm Capital Management Inc. NY boosted its position in SiBone by 113.3% during the first quarter. Paradigm Capital Management Inc. NY now owns 1,126,500 shares of the company’s stock worth $14,228,000 after acquiring an additional 598,300 shares during the last quarter. Cadian Capital Management LP grew its stake in SiBone by 96.8% during the 4th quarter. Cadian Capital Management LP now owns 1,171,100 shares of the company’s stock valued at $23,094,000 after acquiring an additional 576,100 shares in the last quarter. Finally, Wellington Management Group LLP grew its stake in SiBone by 74.7% during the 3rd quarter. Wellington Management Group LLP now owns 853,266 shares of the company’s stock valued at $12,560,000 after acquiring an additional 364,897 shares in the last quarter. Hedge funds and other institutional investors own 98.11% of the company’s stock.

About SiBone

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.